Neimeth International Pharmaceuticals Plc Share Price

Equities

NEIMETH

NGNEIMETH001

Pharmaceuticals

End-of-day quote Nigerian S.E. 23:00:00 28/04/2024 BST 5-day change 1st Jan Change
1.98 NGN 0.00% Intraday chart for Neimeth International Pharmaceuticals Plc +10.00% +2.06%

Financials

Sales 2022 2.92B 2.1M 168M Sales 2023 2.21B 1.59M 127M Capitalization 8.29B 5.97M 477M
Net income 2022 -325M -234K -18.7M Net income 2023 -2.58B -1.86M -148M EV / Sales 2022 2.03 x
Net Debt 2022 3.2B 2.3M 184M Net Debt 2023 2.05B 1.48M 118M EV / Sales 2023 4.68 x
P/E ratio 2022
-8.36 x
P/E ratio 2023
-3.21 x
Employees 202
Yield 2022 *
-
Yield 2023
-
Free-Float 28.29%
More Fundamentals * Assessed data
Dynamic Chart
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fifteen Months Ended December 31, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Fourth Quarter Ended September 30, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
Neimeth International Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended September 30, 2021 CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Third Quarter Ended June 30, 2021 CI
Neimeth International Pharmaceuticals plc Reports Earnings Results for the Second Quarter Ended March 31, 2021 CI
More news
1 week+10.00%
Current month+8.79%
1 month+8.79%
3 months-3.41%
6 months+15.12%
Current year+2.06%
More quotes
1 week
1.81
Extreme 1.81
1.98
1 month
1.64
Extreme 1.64
1.98
Current year
1.64
Extreme 1.64
2.20
1 year
1.39
Extreme 1.39
2.45
3 years
1.26
Extreme 1.26
2.45
5 years
0.37
Extreme 0.37
2.91
10 years
0.35
Extreme 0.3545
2.91
More quotes
Managers TitleAgeSince
Chief Executive Officer - 15/08/23
Director of Finance/CFO - -
Chief Administrative Officer - 31/12/91
Members of the board TitleAgeSince
Director/Board Member - 31/01/97
Chairman 62 31/01/04
Chief Executive Officer - 15/08/23
More insiders
Date Price Change Volume
29/04/24 1.98 0.00% 140,484
26/04/24 1.98 0.00% 112,656
25/04/24 1.98 0.00% 146,455
24/04/24 1.98 +10.00% 3,151,865
23/04/24 1.8 0.00% 33,146

End-of-day quote Nigerian S.E., April 28, 2024

More quotes
Neimeth International Pharmaceuticals Plc is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Co-Amoxiclav, Gyno-Tiocosid, Miniplus, Neimelyn, Norduet, and Normoretic. Veterinary Products include Neimeth Piperazine, Neimycin Soluble Powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, Nimartem, and Pancemol. The Company operates in two geographic regions: Nigeria and Ghana.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. NEIMETH Stock